AVE Science & Technology Co

AVE Science & Technology Co EBITDA Margin

The EBITDA Margin of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 13.10 %. In the previous year, EBITDA Margin was 15.28 % — a change of -14.28% (lower).

EBITDA Margin

13.10 %

YoY

-14.28%

Last updated:

EBITDA Margin of AVE Science & Technology Co is 2025 13.10 % . EBITDA Margin of AVE Science & Technology Co was 2024 15.28 % . It decreases by -14.28% lower compared to the previous year.

The AVE Science & Technology Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
21.51 CNY
Jan 1, 2019
31.52 CNY
Jan 1, 2020
20.78 CNY
Jan 1, 2021
17.75 CNY
Jan 1, 2022
11.82 CNY
Jan 1, 2023
14.50 CNY
Jan 1, 2024
15.28 CNY
Jan 1, 2025
13.10 CNY
The AVE Science & Technology Co EBITDA Margin history
YEAREBITDA MarginYoY
13.10 %-14.28%
15.28 %+5.39%
14.50 %+22.70%
11.82 %-33.44%
17.75 %-14.56%
20.78 %-34.08%
31.52 %+46.54%
21.51 %-5.28%
22.71 %+20.69%
18.82 %+16.62%
16.14 %+26.48%
12.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

EBITDA Margin of AVE Science & Technology Co is 13.10 % in 2025.

EBITDA Margin of AVE Science & Technology Co changed from 15.28 % to 13.10 %, representing a -14.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's AVE Science & Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co